TXG
Income statement / Annual
Last year (2024), 10x Genomics, Inc.'s total revenue was $610.79 M,
a decrease of 1.28% from the previous year.
In 2024, 10x Genomics, Inc.'s net income was -$182.63 M.
See 10x Genomics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$610.79 M |
$618.73 M |
$516.41 M |
$490.49 M |
$298.85 M |
$245.89 M |
$146.31 M |
$71.09 M |
| Cost of Revenue |
$196.30 M
|
$209.41 M
|
$120.39 M
|
$74.09 M
|
$58.47 M
|
$61.03 M
|
$28.66 M
|
$10.56 M
|
| Gross Profit |
$414.48 M
|
$409.31 M
|
$396.02 M
|
$416.40 M
|
$240.38 M
|
$184.86 M
|
$117.65 M
|
$60.53 M
|
| Gross Profit Ratio |
0.68
|
0.66
|
0.77
|
0.85
|
0.8
|
0.75
|
0.8
|
0.85
|
| Research and Development Expenses |
$264.70 M
|
$270.33 M
|
$265.67 M
|
$211.75 M
|
$123.38 M
|
$83.10 M
|
$47.54 M
|
$32.16 M
|
| General & Administrative Expenses |
$0.00
|
$340.03 M
|
$294.60 M
|
$252.86 M
|
$200.43 M
|
$129.33 M
|
$87.24 M
|
$46.54 M
|
| Selling & Marketing Expenses |
$0.00
|
$3.30 M
|
$3.70 M
|
$4.70 M
|
$1.90 M
|
$1.50 M
|
$700,000.00
|
$200,000.00
|
| Selling, General & Administrative Expenses |
$344.34 M
|
$343.33 M
|
$298.30 M
|
$257.56 M
|
$202.33 M
|
$130.83 M
|
$87.94 M
|
$46.74 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$198,000.00
|
-$802,000.00
|
$1.34 M
|
-$186,000.00
|
-$249,000.00
|
$137,000.00
|
| Operating Expenses |
$609.04 M
|
$674.95 M
|
$563.97 M
|
$469.31 M
|
$325.70 M
|
$213.93 M
|
$135.47 M
|
$78.90 M
|
| Cost And Expenses |
$805.34 M
|
$884.36 M
|
$684.35 M
|
$543.40 M
|
$384.17 M
|
$274.96 M
|
$164.13 M
|
$89.46 M
|
| Interest Income |
$18.45 M
|
$16.91 M
|
$6.65 M
|
$206,000.00
|
$1.53 M
|
$2.81 M
|
$1.02 M
|
$308,000.00
|
| Interest Expense |
$4,000.00
|
$33,000.00
|
$476,000.00
|
$866,000.00
|
$1.68 M
|
$3.08 M
|
$2.41 M
|
$811,000.00
|
| Depreciation & Amortization |
$43.71 M
|
$43.62 M
|
$33.01 M
|
$28.25 M
|
$19.02 M
|
$7.07 M
|
$3.91 M
|
$4.31 M
|
| EBITDA |
-$133.99 M |
-$205.11 M |
-$128.49 M |
-$24.60 M |
-$513.77 M |
-$20.89 M |
-$106.08 M |
-$13.63 M |
| EBITDA Ratio |
-0.22
|
-0.33
|
-0.31
|
-0.11
|
-0.28
|
-0.11
|
-0.09
|
-0.19
|
| Operating Income Ratio |
-0.32
|
-0.32
|
-0.33
|
-0.11
|
-0.29
|
-0.12
|
-0.76
|
-0.26
|
| Total Other Income/Expenses Net |
$16.86 M
|
-$53.81 M
|
$5.97 M
|
-$802,000.00
|
-$449.15 M
|
-$1.96 M
|
-$1.63 M
|
-$366,000.00
|
| Income Before Tax |
-$177.70 M
|
-$248.76 M
|
-$161.97 M
|
-$53.72 M
|
-$534.48 M
|
-$31.03 M
|
-$112.40 M
|
-$18.74 M
|
| Income Before Tax Ratio |
-0.29
|
-0.4
|
-0.31
|
-0.11
|
-1.79
|
-0.13
|
-0.77
|
-0.26
|
| Income Tax Expense |
$4.93 M
|
$6.34 M
|
$4.03 M
|
$4.51 M
|
$8.26 M
|
$218,000.00
|
$87,000.00
|
$21,000.00
|
| Net Income |
-$182.63 M
|
-$255.10 M
|
-$166.00 M
|
-$58.22 M
|
-$542.73 M
|
-$31.25 M
|
-$112.49 M
|
-$18.76 M
|
| Net Income Ratio |
-0.3
|
-0.41
|
-0.32
|
-0.12
|
-1.82
|
-0.13
|
-0.77
|
-0.26
|
| EPS |
-1.52 |
-2.18 |
-1.46 |
-0.53 |
-5.37 |
-0.8 |
-8.4 |
-1.62 |
| EPS Diluted |
-1.52 |
-2.18 |
-1.46 |
-0.53 |
-5.37 |
-0.8 |
-8.4 |
-1.62 |
| Weighted Average Shares Out |
$120.45 M
|
$117.17 M
|
$113.86 M
|
$110.35 M
|
$101.15 M
|
$39.06 M
|
$13.39 M
|
$11.59 M
|
| Weighted Average Shares Out Diluted |
$120.45 M
|
$117.17 M
|
$113.86 M
|
$110.35 M
|
$101.15 M
|
$39.09 M
|
$13.39 M
|
$11.59 M
|
| Link |
|
|
|
|
|
|
|
|
